

# PLOS ONE

## R Functions for Analysis of Continuous Glucose Monitor Data

--Manuscript Draft--

<b>Manuscript Number:</b>	PONE-D-19-11955
<b>Article Type:</b>	Research Article
<b>Full Title:</b>	R Functions for Analysis of Continuous Glucose Monitor Data
<b>Short Title:</b>	R package for continuous glucose monitor data
<b>Corresponding Author:</b>	Laura Pyle University of Colorado School of Medicine Aurora, UNITED STATES
<b>Keywords:</b>	blood glucose; continuous glucose monitor; cgm; data management; diabetes; statistics; open-source
<b>Abstract:</b>	Continuous glucose monitoring (CGM) is an essential part of diabetes care. Real-time CGM data are beneficial to patients for daily glucose management, and aggregate summary statistics of CGM measures are valuable to direct insulin dosing and as a tool for researchers in clinical trials. Yet, the various commercial systems still report CGM data in disparate, non-standard ways. Accordingly, there is a need for a standardized, free, open-source approach to CGM data management and analysis. Functions were developed in the free programming language R to provide a rapid, easy, and consistent methodology for CGM data management and analysis. Summary variables calculated by our package compare well to those generated by various CGM software, and our functions provide a more comprehensive list of summary measures available to clinicians and researchers. Consistent handling of CGM data using our R package may facilitate collaboration between research groups and contribute to a better understanding of free-living glucose patterns.
<b>Order of Authors:</b>	Tim Vigers
	Christine L Chan
	Janet Snell-Bergeon
	Petter Bjornstad
	Philip Zeitler
	Gregory Forlenza
	Laura Pyle
<b>Opposed Reviewers:</b>	
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
<b>Financial Disclosure</b>  Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the <a href="#">submission guidelines</a> for detailed requirements. View published research articles from <a href="#">PLOS ONE</a> for specific examples.  This statement is required for submission and <b>will appear in the published article</b> if the submission is accepted. Please make	Funding sources: NIH (www.nih.gov) grants DK094712-04 (GF) and Cystic Fibrosis Foundation (www.cff.org) Therapeutics grants CHAN16A0 and CHAN16GE0 (CC).  The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

sure it is accurate.

#### Unfunded studies

Enter: *The author(s) received no specific funding for this work.*

#### Funded studies

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

\* typeset

#### Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement **will appear in the published article** if the submission is accepted. Please make sure it is accurate. View published research articles from [PLOS ONE](#) for specific examples.

The authors have declared that no competing interests exist.

#### NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

#### Authors with competing interests

Enter competing interest details beginning with this statement:

*I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]*

\* typeset

#### Ethics Statement

Enter an ethics statement for this submission. This statement is required if the study involved:

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

General guidance is provided below. Consult the [submission guidelines](#) for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

N/A

## Format for specific study types

### Human Subject Research (involving human participants and/or tissue)

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

### Animal Research (involving vertebrate animals, embryos or tissues)

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

### Field Research

Include the following details if this study

involves the collection of plant, animal, or

other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

### Data Availability

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

Yes - all data are fully available without restriction

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

**Important:** Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

**Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.**

Available after acceptance

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following:  
*All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

*Data cannot be shared publicly because of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.*

*The data underlying the results presented in the study are available from (include the name of the third party*

<p><i>and contact information or URL).</i></p> <ul style="list-style-type: none"> <li>• This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.</li> </ul> <p>* typeset</p>	
Additional data availability information:	<p>Tick here if the URLs/accession numbers/DOIs will be available only after acceptance of the manuscript for publication so that we can ensure their inclusion before publication.</p>

Laura Pyle  
University of Colorado Anschutz Medical Campus  
13123 E 16th Avenue, A036-B265  
Aurora, Colorado 80045  
303-724-4355  
[laura.pyle@ucdenver.edu](mailto:laura.pyle@ucdenver.edu)

April 26, 2019

Dear Dr. Heber:

I am excited to submit a research article for your consideration for publication in *PLOS One*. In this manuscript, we describe a software package for the R computing language for cleaning and analyzing continuous glucose monitoring (CGM) data. Increasingly, CGMs are considered an essential part of diabetes care, and metrics based on CGM data are being used as outcomes in clinical trials and other research. However, the various commercial systems that are available for summarizing CGM data report the results in non-standardized ways, and, to our knowledge, there is no free, open-source approach to CGM data management and analysis available. In this manuscript, we review common summary measures of glycemia (which are all calculated by our software) describe the development and use of the R package, and compare results obtained using our software to those from commercial software systems.

We hope that this manuscript will assist others in their continuous glucose monitor research and improve collaboration by contributing to a standardized methodology between research groups, allowing a better understanding of free-living glucose patterns in humans.

We would like to suggest one of the following Academic Editors to handle this manuscript: Rosa Corcoy, MD, PhD; Andreas Beyerlein, PhD; Kathleen Bethin, MD, PhD; Antonio Palazón-Bru, PhD.

Some of this work has been presented at the 2019 Advanced Technologies & Treatments for Diabetes (ATTD) conference, but this manuscript has not been published and is not under consideration for publication elsewhere, and we have not had any prior contact with PLOS regarding the manuscript.

Thank you for your consideration.

Sincerely,



Laura Pyle, PhD  
Associate Professor  
Department of Pediatrics, University of Colorado School of Medicine  
Department of Biostatistics and Informatics, Colorado School of Public Health

## R Functions for Analysis of Continuous Glucose Monitor Data

Tim Vigers<sup>1,2,3\*</sup>, B.A., Christine L. Chan<sup>1</sup>, M.D., Janet Snell-Bergeon<sup>2</sup>, Ph.D., Petter Bjornstad<sup>1</sup>, M.D., Philip S. Zeitler<sup>1</sup>, M.D., Ph.D., Gregory Forlenza<sup>2</sup>, M.D., Laura Pyle<sup>1,2,3</sup>, Ph.D.

<sup>1</sup>Department of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, Colorado, United States

<sup>2</sup>Barbara Davis Center, University of Colorado School of Medicine, Aurora, Colorado, United States

<sup>3</sup>Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado

\*Corresponding Author

[Laura.pyle@ucdenver.edu](mailto:Laura.pyle@ucdenver.edu) (LP)



## **Abstract:**

Continuous glucose monitoring (CGM) is an essential part of diabetes care. Real-time CGM data are beneficial to patients for daily glucose management, and aggregate summary statistics of CGM measures are valuable to direct insulin dosing and as a tool for researchers in clinical trials. Yet, the various commercial systems still report CGM data in disparate, non-standard ways. Accordingly, there is a need for a standardized, free, open-source approach to CGM data management and analysis. Functions were developed in the free programming language R to provide a rapid, easy, and consistent methodology for CGM data management and analysis. Summary variables calculated by our package compare well to those generated by various CGM software, and our functions provide a more comprehensive list of summary measures available to clinicians and researchers. Consistent handling of CGM data using our R package may facilitate collaboration between research groups and contribute to a better understanding of free-living glucose patterns.

## Introduction

Continuous glucose monitoring (CGM) technology has transformed diabetes care over the past 15 years by allowing clinicians to measure free-living glucose patterns. During this period, CGM use has increased from < 5% of patients to almost 50% in some age groups [1]. With recent reports detailing the benefits of CGM time in range metrics as predictive of long-term vascular outcomes [2] and as an indicator of glucose management or estimated hemoglobin A1c (HbA1c) [3], CGM use will likely continue to increase in both research and clinical settings. Despite the increasing use of CGM for treatment and research, a standardized, free, open-source approach to data management and analysis is lacking [4].

CGM manufacturers use proprietary algorithms to create reports and calculate summary measures for patients and clinicians. As a result, it may be difficult to compare results obtained using different CGM devices and to understand the sources of variability that could influence CGM outcomes. In addition, research questions may require summary measures that are not available in accompanying reports (e.g., use of a different cut-point for hyperglycemia). Furthermore, use of the summary values provided by each CGM platform sometimes requires that data be entered by hand into a database or spreadsheet prior to analysis. This is a time-consuming and error prone process that will benefit from automation. The use of a free and open source program to analyze raw sensor glucose values will enable researchers to define their own variables of interest and standardize calculation of summary measures across different CGM devices.

There have already been a few attempts to develop such systems, including the EasyGV macro-enabled Excel workbook [5], AGP Report ([agpreport.org](http://agpreport.org)), and Tidepool ([tidepool.org](http://tidepool.org)). However, there are reports suggesting that EasyGV poorly matches other calculations of mean

amplitude of glycemic excursion (MAGE) [6], and it does not permit the various definitions of a significant excursion (i.e. greater than 1 standard deviation (SD), 2 SDs, etc.). Although Tidepool appears to be an excellent option for patients and clinicians, it is not free for use in research, and many smaller investigator-initiated studies cannot afford the additional expense. Also, their open source code requires significant coding knowledge in multiple programming languages which limits accessibility and widespread use.

To address this need, we have developed a package written entirely in the statistical programming language R (R Foundation for Statistical Computing, Vienna, Austria). The package currently works with data from Diasend ([www.diasend.com](http://www.diasend.com)), Dexcom ([www.dexcom.com](http://www.dexcom.com)), iPro 2 (<http://professional.medtronicdiabetes.com/ipro2-professional-cgm>), Libre ([www.freestylelibre.us](http://www.freestylelibre.us)), and Carelink ([www.medtronicdiabetes.com/products/carelink-personal-diabetes-software](http://www.medtronicdiabetes.com/products/carelink-personal-diabetes-software)), with plans to add support for other platforms as CGM technology advances. Additionally, data can be manually formatted to work with these functions if necessary. The package is available on The Comprehensive R Archive Network (CRAN) under the name ‘cgmanalysis’ and the source code can be found at <https://github.com/childhealthbiostatcore/R-Packages>, which allows for version control and forking if users need to alter functionality, and includes a short user guide for those with limited R experience.

## Summary Measures of Glycemia

Although CGM is not a new technology, there is still debate regarding the advantages and disadvantages of various CGM metrics for use in clinical care and as research outcomes. The American Diabetes Association (ADA) recently proposed a set of key metrics for CGM analysis

[7], all of which are calculated by our code, in addition to the glucose management index (GMI) [3], time in range [2], and other variables proposed by Hernandez et al.[8]. An easy method to calculate these important summary variables from a variety of sources of CGM data has the potential to contribute to the standardization of the use of these metrics. A list of summary variables produced by our default code is available in **Table 1**, and **Table 2** provides comparisons between the package and proprietary software. The code can be easily modified to include further variables of interest, to be released in future version updates. Further, because the package is open source, individual users can create their own modifications.

## Methods

### Package Design

Our package consists of three simple functions: `cleandata()`, `cgmvariables()`, and `cgmreport()`. The data cleaning function iterates through a directory of CGM data exports and produces new files that then serve as input to the CGM variable calculator and the CGM report generator. The initial directory can contain files from different sources, as the function identifies the relevant timestamp and glucose values for each file format. By default, the cleaning function will fill in gaps in glucose data less than 20 minutes long using linear interpolation. It will also remove 24-hour periods containing gaps larger than 20 minutes, so that there will be an equal number of daytime and nighttime values, important for calculating some variables, such as AUC. The user can specify a different maximum gap to fill by interpolation and can also choose whether to remove days with larger gaps. Ideally, the CGM data should be exported and then cleaned using this package, and not manually edited. However, if a file does require manual data

editing, these functions will work on the three-column format detailed in the package documentation.

Once the data have been cleaned, the CGM variables described in **Table 1** are calculated using the `cgmvariables()` function. By default, blood glucose must be above a threshold for at least 35 minutes or below a threshold for at least 10 minutes to count as an excursion, but these parameters can be changed by the user if necessary. Likewise, daytime (e.g. for daytime vs. nighttime AUC or maximum glucose) is defined as 6:00 to 22:00 by default, but these can be set depending on user needs. MAGE is calculated using Baghurst's algorithm [9], which we have coded in R. By default, the function includes blood glucose excursions greater than 1 SD from the mean in calculation of MAGE, but there are options for 1.5 SD and 2 SD as well.

**Table 1: Summary Measures of Glycemia**

CGM Variable	Definition
percent_cgm_wear	The number of sensor readings as a percentage of the number of potential readings (given time worn).
average_sensor	Mean of all sensor glucose values
estimated_a1c	Estimated HbA1c based on the equation: $(46.7 + \text{average glucose in mg/dL}) / 28.7$ [1]
gmi	Glucose management indicator based on the equation: $3.31 + (0.02392 \times \text{average glucose in mg/dL})^7$
q1_sensor	First quartile sensor glucose value
median_sensor	Median sensor glucose value
q3_sensor	Third quartile sensor glucose value
standard_deviation	Standard deviation of all sensor glucose values
cv	Coefficient of variation of all sensor glucose values (SD/mean)
min_sensor	Minimum of all sensor glucose values
max_sensor	Maximum of all sensor glucose values
excursions_over_***	The number of local glucose peaks with an amplitude greater than *** mg/dL
min_spent_over_***	The total length of time that sensor glucose was at or above *** mg/dL
percent_time_over_***	Minutes spent above *** mg/dL, as a

	percentage of the total time CGM was worn
avg_excur_over_***_per_day	The number of glucose peaks above *** mg/dL averaged per 24-hour period of CGM wear
min_spent_under_**	The total length of time that sensor glucose was at or below ** mg/dL
percent_time_under_**	Minutes spent below ** mg/dL, as a percentage of the total time CGM was worn
min_spent_70_180	Minutes spent in the range 70 – 180 mg/dL (inclusive)
percent_time_70_180	Minutes spent in the range 70 – 180 mg/dL (inclusive), as a percentage of the total time CGM was worn
daytime_***	*** of all sensor glucose values during specified daytime hours
nighttime_***	*** of all sensor glucose values during specified nighttime hours
auc	Approximate area under the sensor glucose curve, calculated using the trapezoidal rule
r_mage	MAGE calculated according to Baghurst's algorithm
j_index	Calculated based on the equation: $0.324 \times (\text{average glucose in mg/dL} + \text{standard deviation of glucose levels})^2$ <sup>11</sup>
conga	Continuous overall net glycemic action, default n = 1 hour <sup>11</sup>
modd	Mean of daily differences
lbgi	Low blood glucose index
hbgi	High blood glucose index

Our code was originally written to produce data tables for upload to a Research Electronic Data Capture (REDCap) database [10], which influenced the selection of variable names in the final output. These names can be changed in the code itself or by simply editing the function's output. These variables are stored in separate columns of a new data frame (the function's output), with each record identified by the patient ID.

In addition to producing calculated variables, our package can also plot CGM data in a few ways. First, the function concatenates all the CGM data in the specified directory into one data table and plots the aggregate data in the style of the standard AGP report

(<http://www.agpreport.org>), the aggregate daily overlay (ADO). This method uses Tukey smoothing after rounding each timepoint to the nearest 10-minute mark, then plots the median, inter-quartile range, and 5 and 95 percentiles at each time of day (with plans to add more options in the future). The package also produces a similar aggregate plot with a Loess-smoothed (locally estimated scatterplot smoothing) average overlaid on points representing every single glucose value. For smaller data sets, this type of plot gives a meaningful overview of daily glucose trends. Finally, the third type of plot uses a Loess-smoothed average for each patient with glucose values color-coded by participant.


## Comparison of cgmanalysis package and proprietary software

Our functions were compared to proprietary CGM software using clinically collected data from iPro 2, Carelink 670G, Dexcom Clarity, and Diasend. The data were exported from each platform, formatted using the `cleandata()` function, then summarized using the `cgmvariables()` and `cgmreport()` functions. The data were not cleaned prior to plotting and summary variable calculation, and summary variable parameters were altered from default (e.g. defining an excursion as 15 minutes above or below threshold for iPro 2 data) in order to better match the CGM results. Because each CGM device provides different and limited summary variables, we were only able to compare a small subset of our package's output and were not able to directly test more complex variables, such as MAGE or CONGA.

## Results

**Fig 1** is an example of the ADO plot made using approximately 25,000 simulated CGM values, and **Fig 2** is the version of the ADO with Loess smoothing, using the same data as in **Fig 1**. **Fig 3** is the patient-specific plot, made with a subset of the simulated data.


143 **Fig 1: Aggregate Daily Overlay (Tukey Smoothing)**



144

145 **Fig 2: Aggregate Daily Overlay (Loess Smoothing)**

146 **Fig 3: Daily Overlay per Subject (LOESS Smoothing)**



147

148 **Table 2** shows the results of summary variable comparisons between four different  
149 proprietary CGM devices and our cgmanalysis package. Most of the differences in these  
150 comparisons are small and the result of rounding. Overall the package appears to be capable of  
151 reproducing proprietary calculations when run with non-default settings, although in the  
152 comparison to the iPro 2, there was a difference of 1 high excursion.

153



**Table 2: Summary Variable Comparisons**

A. iPro 2 software (high excursion defined as > 140 mg/dL for 15 minutes, low defined as < 60 mg/dL for 15 minutes)

	cgmanalysis	iPro
# Sensor Values	2000	2000
Highest	282	282
Lowest	70	70
Average	126.87	127
Standard Dev	30.79	31
# High Excursions	31	32
# Low Excursions	0	0
% Time Above 140	24.85	24
% Time Below 60	0	0

B. Carelink 670G

	cgmanalysis	Carelink 670G
Average	123.65	124
Standard Dev	37.53	38

C. Dexcom Clarity

	cgmanalysis	Dexcom Clarity
Average	175.68	176
Standard Dev	67.10	68
Time in Range	55.66	56

D. Diasend


	cgmanalysis	Diasend
# Sensor Values	184	184
Highest	411	411
Lowest	54	54
Average	193.23	193
Standard Dev	89.67	89
Values above 200	44.57%	44.57%

**Figs 4a-d** show the comparisons of the graphical outputs produced by the proprietary software and the cgmanalysis package. In the graphs produced by the cgmanalysis package, glycemic patterns at each hour of the day are clearly visible and match the CGM device outputs well. However, some of the proprietary software appear to apply different smoothing algorithms, resulting in slightly different patterns across time.

**Fig 4a: “cgmanalysis” Package Plots Compared to iPro 2 Daily Overlay**

Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay (Loess Smoothing), iPro 2 Daily Overlay


**Fig 4a Tukey AGP (Top Left) Legend**



**Fig 4b: “cgmanalysis” Package Plots Compared to Carelink 670G Daily Overlay**

Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay (Loess Smoothing), Carelink 670G Daily Overlay

**Fig 4b Tukey AGP (Top Left) Legend**



**Fig 4c: “cgmanalysis” Package Plots Compared to Dexcom Clarity Daily Overlay**

Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay (Loess Smoothing), Dexcom Daily Overlay


**Fig 4c Tukey AGP (Top Left) Legend**

-- 5th & 95th Percentile

Interquartile Range

Median

**Fig 4c Dexcom Clarity (Bottom) Legend**



**Fig 4d Tukey AGP (Top Left) Legend**

-- 5th & 95th Percentile

Interquartile Range

Median

**Fig 4d Tukey AGP (Bottom) Legend**

Monday Tuesday Wednesday Thursday Friday Saturday Sunday Interval mean value

**Fig 4d: “cgmanalysis” Package Plots Compared to Diasend Daily Overlay**

Clockwise from top left: Aggregate Daily Overlay (Tukey Smoothing), Aggregate Daily Overlay (Loess Smoothing), Diasend Daily Overlay

## Discussion

The summary variables produced by the cgmanalysis package match those from the proprietary software for all platforms assessed, and differences are mainly due to rounding discrepancies. Compared to the iPro 2, the number of high excursions differed by 1. Without access to the iPro algorithms we are unable to determine why these counts disagree, but the difference is not likely of clinical significance. The graphical outputs from the cgmanalysis package are similar to the CGM device output in terms of the glycemic patterns by hour of day, although there are small differences, likely due different smoothing algorithms.

There are several limitations to our comparison of the cgmanalysis package to the proprietary software output. CGM devices only calculate a few summary variables, and accordingly it is difficult to test this package cohesively. Also, gold standard calculations do not exist for many of these variables, which makes verifying our results difficult. We hope that by making this package freely available and open source, these limitations will be minimized through widespread testing. Perhaps the greatest limitation to the software itself is the lack of an easy to use graphical user interface (GUI), which may prevent its use by clinicians with limited programming experience. We have included detailed documentation in the CRAN package, as well as a new-user guide on GitHub, but using the package still requires enough technical knowledge that it may be inaccessible to some users. None of the authors are software engineers, and the package is undoubtedly less efficient than it could be. Again, we hope that the free and open source nature will contribute significantly to improving the code over time, both as a result of outside contributions and our own planned updates.

224           In conclusion, our software provides a standardized, free, open-source approach to  
225   manage and analyze CGM data, enabling sharing of data across technology platforms,  
226   collaboration between research groups, and more effective use of the growing pool of CGM data.  
227   The advantage of using R functions rather than licensed statistical software, or a web-based or  
228   desktop application, is that R is freely available and open source. Clinicians or investigators can  
229   alter the code according to their needs and anyone can contribute to the development of the  
230   program, as CGM research and technology advance.

231

232

## References

1. DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. *Pediatr Diabetes*. 2018;19(7):1271-1275.
2. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. *Diabetes Care*. 2018.
3. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. *Diabetes Care*. 2018;41(11):2275-2280.
4. Hernandez TL, Barbour LA. A Standard Approach to Continuous Glucose Monitor Data in Pregnancy for the Study of Fetal Growth and Infant Outcomes. *Diabetes Technology & Therapeutics*. 2013;15(2):172-179.
5. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. *Diabetes Technol Ther*. 2011;13(9):921-928.
6. Sechterberger MK, Luijf YM, DeVries JH. Poor agreement of computerized calculators for mean amplitude of glycemic excursions. *Diabetes Technol Ther*. 2014;16(2):72-75.
7. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care*. 2017;40(12):1631-1640.
8. Hernandez TL, Barbour LA. A standard approach to continuous glucose monitor data in pregnancy for the study of fetal growth and infant outcomes. *Diabetes Technol Ther*. 2013;15(2):172-179.
9. Baghurst PA. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. *Diabetes Technol Ther*. 2011;13(3):296-302.
10. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-381.




Figure 2

[Click here to download Figure Fig2.eps](#)






Figure 3

[Click here to download Figure Fig3.eps](#)




Figure 4a

[Click here to download Figure Fig4a.eps](#)






Figure 4b

[Click here to download Figure Fig4b.eps](#)






Figure 4c

[Click here to download Figure Fig4c.eps](#)






Figure 4e

[Click here to download Figure Fig4d.eps](#)

